Cargando…
Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study
BACKGROUND: The post-COVID syndrome is the various physical and neuropsychiatric symptoms after the acute phase of COVID-19. The understanding of pathophysiology of this syndrome and its treatment need to further studies. This study aimed to present three cases of neuropsychiatric symptoms after COV...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569165/ https://www.ncbi.nlm.nih.gov/pubmed/36267491 http://dx.doi.org/10.1007/s40200-022-01138-5 |
_version_ | 1784809800387788800 |
---|---|
author | Shafiee, Gita Arastou, Tohid Heshmat, Ramin Jamshidi, Ahmad Reza Larijani, Bagher Arzaghi, Seyed Masoud |
author_facet | Shafiee, Gita Arastou, Tohid Heshmat, Ramin Jamshidi, Ahmad Reza Larijani, Bagher Arzaghi, Seyed Masoud |
author_sort | Shafiee, Gita |
collection | PubMed |
description | BACKGROUND: The post-COVID syndrome is the various physical and neuropsychiatric symptoms after the acute phase of COVID-19. The understanding of pathophysiology of this syndrome and its treatment need to further studies. This study aimed to present three cases of neuropsychiatric symptoms after COVID-19 and effective treatments in these patients. CASE PRESENTATION: Three patients with new or progressively neuropsychiatric symptoms such as seizures, attention difficulties, insomnia, confusion and etc., were referred to our clinic about 8 months after severe COVID-19 infection. The patients were assessed with extensive workup includes a neurological exam, brain MRI, LORETA scan, and biochemical and levels of inflammatory serum markers. All patients had elevated levels of TNF-α, poor neurological exam, and abnormal reports of MRI or LORETA scan. Diagnosis of post- COVID neuropsychiatric complications was made for the patients.TNF inhibition with Adalimumab (40 mg/weekly for a month) was initiated for the patients and led to a dramatic improvement of all symptoms. CONCLUSIONS: To our knowledge, this report is the first case series study that suggests TNF inhibitors in the treatment of post-COVID-19 syndrome, especially neuropsychological complications. However, future studies should evaluate the best therapeutic options for this syndrome. |
format | Online Article Text |
id | pubmed-9569165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95691652022-10-16 Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study Shafiee, Gita Arastou, Tohid Heshmat, Ramin Jamshidi, Ahmad Reza Larijani, Bagher Arzaghi, Seyed Masoud J Diabetes Metab Disord Case Report BACKGROUND: The post-COVID syndrome is the various physical and neuropsychiatric symptoms after the acute phase of COVID-19. The understanding of pathophysiology of this syndrome and its treatment need to further studies. This study aimed to present three cases of neuropsychiatric symptoms after COVID-19 and effective treatments in these patients. CASE PRESENTATION: Three patients with new or progressively neuropsychiatric symptoms such as seizures, attention difficulties, insomnia, confusion and etc., were referred to our clinic about 8 months after severe COVID-19 infection. The patients were assessed with extensive workup includes a neurological exam, brain MRI, LORETA scan, and biochemical and levels of inflammatory serum markers. All patients had elevated levels of TNF-α, poor neurological exam, and abnormal reports of MRI or LORETA scan. Diagnosis of post- COVID neuropsychiatric complications was made for the patients.TNF inhibition with Adalimumab (40 mg/weekly for a month) was initiated for the patients and led to a dramatic improvement of all symptoms. CONCLUSIONS: To our knowledge, this report is the first case series study that suggests TNF inhibitors in the treatment of post-COVID-19 syndrome, especially neuropsychological complications. However, future studies should evaluate the best therapeutic options for this syndrome. Springer International Publishing 2022-10-15 /pmc/articles/PMC9569165/ /pubmed/36267491 http://dx.doi.org/10.1007/s40200-022-01138-5 Text en © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Case Report Shafiee, Gita Arastou, Tohid Heshmat, Ramin Jamshidi, Ahmad Reza Larijani, Bagher Arzaghi, Seyed Masoud Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title | Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title_full | Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title_fullStr | Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title_full_unstemmed | Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title_short | Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study |
title_sort | post covid-19 neuropsychiatric complications and therapeutic role for tnf-α inhibitors: a case series study |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569165/ https://www.ncbi.nlm.nih.gov/pubmed/36267491 http://dx.doi.org/10.1007/s40200-022-01138-5 |
work_keys_str_mv | AT shafieegita postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy AT arastoutohid postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy AT heshmatramin postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy AT jamshidiahmadreza postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy AT larijanibagher postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy AT arzaghiseyedmasoud postcovid19neuropsychiatriccomplicationsandtherapeuticrolefortnfainhibitorsacaseseriesstudy |